Product Images Clopidogrel
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Clopidogrel NDC 50090-5868 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - clopidogrel fig1
Figure 1 shows the effects on the exposure to the active metabolite of Clopidogrel (a medication used to prevent blood clots) when co-administered with different Proton Pump Inhibitors (PPIs) at various doses. The figure displays the mean and 90% confidence interval for the effect of each PPI on the area under the curve (AUC) of the active metabolite. The PPIs included in the study are Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole, at doses of 60 mg, 30 mg, 80 mg, and 80 mg respectively. The figure also illustrates the change in exposure relative to when Clopidogrel Bisulfate 75 mg is administered alone.*
Figure 2: Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study - clopidogrel fig2
The given text appears to be a table showing the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for two treatments (Plagebo + aspirin and Clopidogrel Bisulfate + aspirin) over a span of 12 months of follow-up. The table includes the percentage value of the cumulative event rate (%), along with the number of events (N) in each treatment group. Additionally, there is a significance value (P=0.00009) provided at the end of the text.*
Figure-3 - clopidogrel fig3
Figure 4: Cumulative Event Rates for Death in the COMMIT Study - clopidogrel fig4
This text appears to be a summary of a study evaluating the effects of a treatment (possibly Clopidogrel) on mortality rates. The text mentions the number of deaths in a placebo group (1845, 8.1%) and a Clopidogrel group (1726, 7.5%). It also states a 7% proportional risk reduction (p = 0.03) associated with the treatment. The text also includes a graph with days since randomization on the x-axis, but the details are not readable. Overall, the text suggests that the treatment may have a positive impact on reducing mortality rates.*
Figure 5: Cumulative Event Rates for the Combined Endpoint Re-Infarction, Stroke or Death in the COMMIT Study - clopidogrel fig5
This text appears to be a comparison between two treatments, "Placeb" and "Clopidogrel", in terms of their effectiveness in reducing certain events (possibly related to health or medical conditions) over a period of 28 days. The text includes percentages and mentions events such as death, re-infarction, and stroke. The data suggests that Clopidogrel may have a lower risk of these events compared to Placeb.*
Figure 6: Effects of Adding Clopidogrel Bisulfate to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study - clopidogrel fig6
Figure 7: Fatal or Non-Fatal Vascular Events in the CAPRIE Study - clopidogrel fig7
Figure 8: Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study - clopidogrel fig8
Chemical Structure - clopidogrel str
Label Image - lbl500905868
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.